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Thank you for your important protocol focusing on identifying and distinguishing isphenotypes of eczema. Our understanding of eczema has evolved beyond identifying skin barrier abnormalities in skin barrier proteins, such as filaggrin or loricrin, and newer literature is also examining variations in lipid composition (lipidomics), and immune pathways (Brunner et al JACI 2018) . This may vary between age, and ethnicities; for example, in Asian patients, Th17 pathways may predominate resulting in a more psoriasiform phenotype (Noda et al JACI 2015) . In evaluating secondary characteristics, I would encourage you to be inclusive of these newer distinguishing immunophenotypic features as they will likely play a role in therapeutic selection; or, alternatively, please specify in the protocol that focus will be on clinical and not molecular phenotypes. Additionally, consideration for associated diagnosis of food allergy should also be mentioned as this may also relate to atopic dermatitis phenotype, please see Roduit et al in JAMA (Noda et al JACI 2015) . In evaluating secondary characteristics, I would encourage you to be inclusive of these newer distinguishing immunophenotypic features as they will likely play a role in therapeutic selection; or, alternatively, please specify in the protocol that focus will be on clinical and not molecular phenotypes.
Thank you for highlighting some of the new developments in this field. We do intend to review phenotypes including both clinical and non-clinical facets of the disease, so to make this clearer we have added the following:
 'Recent '-omics' research has further highlighted a role of lipid composition and immune pathways in disease pathology and phenotypic presentation' to the first paragraph of the introduction;  'Th17 activation' to the third paragraph as an example of an endophenotype;  '… and could include any feature of the disease, including clinical presentation, and genetic, immunological or molecular characteristics, provided one of the primary or secondary aims was to define or identify subtypes/classifications/phenotypes of atopic dermatitis, to the Eligibility Criteria under Methods and Analysis.
Additionally, consideration for associated diagnosis of food allergy should also be mentioned as this may also relate to atopic
We will certainly collect this information if it is available in the results of relevant papers. We now mention this at the end of the third We have added a paragraph at the end of the 'Methods and Results' section:
The research questions have been developed in consultation with Dr Sinéad Langan's Senior Clinical fellowship steering committee, which includes patient representation. The authors would like to thank Amanda Roberts for her contributions to discussions.
